The stock's fall snapped a three-day winning streak.

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

This was the stock's second consecutive day of gains.

Vertex also benefited from continued growth in its cystic fibrosis business." Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

Why a weaker Harvard would mean a weaker Massachusetts The nation’s oldest university helps power the region’s economy in all sorts of ways.

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.